Ligand Pharmaceuticals (LGND) reported Q2 adjusted earnings Thursday of $2.37 per diluted share, up from $1.60 a year earlier.
Analysts polled by FactSet expected $1.95.
Revenue for the quarter ended June 30 was $63.7 million, up from $47.6 million a year earlier.
Analysts polled by FactSet expected $60.9 million.
The company raised its full-year 2026 adjusted earnings guidance to $9.00 to $9.50 per diluted share from its prior outlook of $8.50 to $9.50 and reaffirmed its revenue guidance of $270 million to $310 million. Analysts polled by FactSet expect adjusted earnings of $9.21 per share and revenue of $287.4 million.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments